antiVEGFlääkeinjektioilla

Anti-VEGF (vascular endothelial growth factor) injections are a class of medications used to treat various eye conditions, primarily wet age-related macular degeneration (AMD) and diabetic macular edema. These injections work by inhibiting the production of VEGF, a protein that contributes to the growth of abnormal blood vessels in the eye, which can lead to vision loss.

The most commonly used anti-VEGF injections include bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), and pegaptanib (Macugen). Each of these medications has its own mechanism of action and is administered via injection into the vitreous, the gel-like substance that fills the center of the eye.

Anti-VEGF injections are typically administered every 4 to 8 weeks, depending on the specific condition being treated and the response to the medication. The injections are usually performed in a clinical setting by an ophthalmologist or optometrist.

While anti-VEGF injections have been shown to be effective in improving vision and reducing the progression of eye conditions, they are not without risks. Potential side effects may include eye irritation, inflammation, and increased risk of retinal detachment. Additionally, there is a risk of developing anti-VEGF-related macular edema, a condition where the injections themselves can cause fluid to accumulate in the macula, leading to vision loss.

It is important for patients to discuss the benefits and risks of anti-VEGF injections with their healthcare provider to make an informed decision about whether this treatment is appropriate for them. Regular follow-up appointments are essential to monitor the effectiveness of the treatment and to address any potential side effects.